Nofetumomab merpentan
Nofetumomab Merpentan (also known as Verluma) is a monoclonal antibody designed for the treatment of various types of cancer. It was developed by Pharmacia and later acquired by Novartis.
History[edit | edit source]
Nofetumomab Merpentan was initially developed by Pharmacia, a Swedish pharmaceutical company. After the acquisition of Pharmacia by Pfizer in 2003, the development rights for Nofetumomab Merpentan were transferred to Novartis.
Mechanism of Action[edit | edit source]
Nofetumomab Merpentan is a monoclonal antibody that targets the carcinoembryonic antigen (CEA), a protein often overexpressed in cancer cells. By binding to this antigen, Nofetumomab Merpentan can help the immune system recognize and destroy cancer cells.
Clinical Trials[edit | edit source]
Several clinical trials have been conducted to evaluate the efficacy and safety of Nofetumomab Merpentan in various types of cancer, including non-small cell lung cancer (NSCLC), colorectal cancer, and breast cancer.
Side Effects[edit | edit source]
Like all medications, Nofetumomab Merpentan can cause side effects. The most common side effects reported in clinical trials include nausea, vomiting, and fatigue.
Current Status[edit | edit source]
As of 2021, Nofetumomab Merpentan is not currently approved for use in any country. However, research is ongoing to further evaluate its potential as a cancer treatment.
See Also[edit | edit source]
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.Contributors: Prab R. Tumpati, MD